The pathway involving RANK and RANKL is recognized as a predominant mechanism underpinning the degradation of bone integrity and loss in conditions like osteoporosis and metastatic bone diseases.269,270 By binding to RANKL, denosumab effectively obstructs the formation, function, and longevity of osteoclasts, thus leading to a reduction in bone resorption.271 Marketed under the brand names Prolia and Xgeva by Amgen, Denosumab is indicated for a variety of clinical scenarios characterized by elevated bone resorption rates or significant fracture risk. The gene discussed is TNFSF11; the disease is osteoporosis.